JP2019529408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529408A5 JP2019529408A5 JP2019514208A JP2019514208A JP2019529408A5 JP 2019529408 A5 JP2019529408 A5 JP 2019529408A5 JP 2019514208 A JP2019514208 A JP 2019514208A JP 2019514208 A JP2019514208 A JP 2019514208A JP 2019529408 A5 JP2019529408 A5 JP 2019529408A5
- Authority
- JP
- Japan
- Prior art keywords
- component
- weight
- preliminary preparation
- ethanol
- preparation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 3
- 239000004973 liquid crystal related substance Substances 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 12
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 claims 7
- 229960005032 treprostinil Drugs 0.000 claims 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 3
- 239000004615 ingredient Substances 0.000 claims 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 239000006184 cosolvent Substances 0.000 claims 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 235000010469 Glycine max Nutrition 0.000 claims 1
- 244000068988 Glycine max Species 0.000 claims 1
- 208000003782 Raynaud disease Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 235000019445 benzyl alcohol Nutrition 0.000 claims 1
- 150000001982 diacylglycerols Chemical class 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 150000003462 sulfoxides Chemical class 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- IQKAWAUTOKVMLE-ZSESPEEFSA-M treprostinil sodium Chemical class [Na+].C1=CC=C(OCC([O-])=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 IQKAWAUTOKVMLE-ZSESPEEFSA-M 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1615754.7 | 2016-09-15 | ||
| GBGB1615754.7A GB201615754D0 (en) | 2016-09-15 | 2016-09-15 | Formulations |
| GB1621277.1 | 2016-12-14 | ||
| GBGB1621277.1A GB201621277D0 (en) | 2016-12-14 | 2016-12-14 | Formulations |
| PCT/EP2017/073359 WO2018050864A1 (en) | 2016-09-15 | 2017-09-15 | Prostacyclin analogue formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529408A JP2019529408A (ja) | 2019-10-17 |
| JP2019529408A5 true JP2019529408A5 (enExample) | 2020-10-22 |
| JP7527785B2 JP7527785B2 (ja) | 2024-08-05 |
Family
ID=59887281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514208A Active JP7527785B2 (ja) | 2016-09-15 | 2017-09-15 | プロスタサイクリン類似体製剤 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11369617B2 (enExample) |
| EP (1) | EP3512495B1 (enExample) |
| JP (1) | JP7527785B2 (enExample) |
| KR (1) | KR20190083645A (enExample) |
| CN (1) | CN109715138B (enExample) |
| AU (1) | AU2017328630B2 (enExample) |
| CA (1) | CA3036307A1 (enExample) |
| DK (1) | DK3512495T3 (enExample) |
| ES (1) | ES2933175T3 (enExample) |
| IL (1) | IL265270B (enExample) |
| LT (1) | LT3512495T (enExample) |
| MX (1) | MX390136B (enExample) |
| PL (1) | PL3512495T3 (enExample) |
| PT (1) | PT3512495T (enExample) |
| RU (1) | RU2757903C2 (enExample) |
| SI (1) | SI3512495T1 (enExample) |
| WO (1) | WO2018050864A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109150387B (zh) | 2017-06-16 | 2023-04-28 | 华为技术有限公司 | 发送参考信号的方法、接收参考信号的方法和通信装置 |
| WO2020240018A1 (en) | 2019-05-29 | 2020-12-03 | Camurus Ab | Administration device & regime |
| EP4173614A4 (en) * | 2020-06-30 | 2024-08-14 | Chong Kun Dang Pharmaceutical Corp. | Injectable composition comprising gnrh derivatives |
| WO2022067336A1 (en) * | 2020-09-25 | 2022-03-31 | Algorithm Sciences, Inc. | Compositions and methods for vasodilator delivery |
| WO2024107096A1 (en) * | 2022-11-14 | 2024-05-23 | Camurus Ab | Treprostinil formulations |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4125255A1 (de) | 1991-07-31 | 1993-02-04 | Knoll Ag | Prostaglandin e (pfeil abwaerts)1(pfeil abwaerts)-formulierung |
| CA2168260C (en) | 1993-07-28 | 2000-04-11 | Marianna Foldvari | Biphasic multilamellar lipid vesicles |
| SE0201659D0 (sv) | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Modified release pharmaceutical formulation |
| ES2670872T3 (es) * | 2003-05-22 | 2018-06-01 | United Therapeutics Corporation | Polimorfo de una sal de dietanolamina de treprostinil |
| EP1768650B1 (en) * | 2004-06-04 | 2008-07-16 | Camurus Ab | Liquid depot formulations |
| GB0412530D0 (en) * | 2004-06-04 | 2004-07-07 | Camurus Ab | Formulation |
| EP1796653A2 (en) * | 2004-07-26 | 2007-06-20 | Actelion Pharmaceuticals Ltd. | Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation |
| WO2006075123A1 (en) | 2005-01-14 | 2006-07-20 | Camurus Ab | Topical bioadhesive formulations |
| ES2343641T3 (es) | 2005-01-14 | 2010-08-05 | Camurus Ab | Formulaciones bioadhesivas topicas. |
| CN101217940B (zh) | 2005-06-06 | 2013-03-27 | 卡穆鲁斯公司 | Glp-1类似物制剂 |
| CN103702662B (zh) | 2011-05-25 | 2018-07-20 | 卡穆鲁斯公司 | 控制释放肽制剂 |
| EP2741781A1 (en) | 2011-08-12 | 2014-06-18 | Ascendis Pharma A/S | Carrier-linked treprostinil prodrugs |
| US9872864B2 (en) | 2011-08-12 | 2018-01-23 | Ascendis Pharma A/S | Sustained release composition of prostacyclin |
| WO2013038460A1 (ja) | 2011-09-16 | 2013-03-21 | 株式会社日立製作所 | 画像表示システム及びその方法 |
| CN104093399B (zh) * | 2011-12-05 | 2018-03-13 | 卡穆鲁斯公司 | 鲁棒性控释肽制剂 |
| AU2013294915C1 (en) * | 2012-07-26 | 2019-11-21 | Camurus Ab | Opioid formulations |
| JP6357481B2 (ja) | 2012-11-30 | 2018-07-11 | インスメッド， インコーポレイテッド | プロスタサイクリン化合物およびプロスタサイクリン化合物を使用する方法 |
| KR101586790B1 (ko) | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | 음이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
| WO2015138423A1 (en) | 2014-03-11 | 2015-09-17 | Insmed Incorporated | Prostacylin compositions and methods for using the same |
| GB201419091D0 (en) | 2014-10-27 | 2014-12-10 | Camurus Ab | Formulations |
| US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
-
2017
- 2017-09-15 DK DK17768124.4T patent/DK3512495T3/da active
- 2017-09-15 CN CN201780056712.7A patent/CN109715138B/zh active Active
- 2017-09-15 WO PCT/EP2017/073359 patent/WO2018050864A1/en not_active Ceased
- 2017-09-15 MX MX2019002999A patent/MX390136B/es unknown
- 2017-09-15 SI SI201731280T patent/SI3512495T1/sl unknown
- 2017-09-15 JP JP2019514208A patent/JP7527785B2/ja active Active
- 2017-09-15 KR KR1020197008219A patent/KR20190083645A/ko not_active Ceased
- 2017-09-15 PL PL17768124.4T patent/PL3512495T3/pl unknown
- 2017-09-15 AU AU2017328630A patent/AU2017328630B2/en active Active
- 2017-09-15 ES ES17768124T patent/ES2933175T3/es active Active
- 2017-09-15 RU RU2019108832A patent/RU2757903C2/ru active
- 2017-09-15 LT LTEPPCT/EP2017/073359T patent/LT3512495T/lt unknown
- 2017-09-15 US US16/333,448 patent/US11369617B2/en active Active
- 2017-09-15 EP EP17768124.4A patent/EP3512495B1/en active Active
- 2017-09-15 CA CA3036307A patent/CA3036307A1/en active Pending
- 2017-09-15 IL IL265270A patent/IL265270B/en unknown
- 2017-09-15 PT PT177681244T patent/PT3512495T/pt unknown
-
2022
- 2022-06-09 US US17/836,120 patent/US20220387445A1/en not_active Abandoned
-
2024
- 2024-11-12 US US18/945,113 patent/US20250319097A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7250689B2 (ja) | 活性化合物のための局所送達系 | |
| JP2013500239A5 (enExample) | ||
| ES2145115T4 (es) | Composiciones inyectables a base de derivados de taxanos. | |
| ES2682075T3 (es) | Formulaciones para el tratamiento de dolor de tejido profundo | |
| ES2958524T3 (es) | Isomiosmina para uso en el tratamiento de enfermedades autoinmunes | |
| PT1818041E (pt) | Composição farmacêutica e/ou cosmética contendo um organossiloxano e um fosfolípido | |
| BR112013019732B1 (pt) | Composição farmacêutica e seu uso no tratamento de doenças cardiovasculares | |
| BR112015015870B1 (pt) | Uso de uma composição farmacêutica | |
| CN109010255B (zh) | 阿片样物质制剂 | |
| RS61377B1 (sr) | Opioidne formulacije | |
| KR20120129864A (ko) | 소포성 제형 | |
| ES2823589T3 (es) | Formulaciones farmacéuticas para la administración subcutánea de furosemida | |
| BR112020023741A2 (pt) | filme, métodos de tratamento de condições em pacientes humanos e de fabricação de filmes e uso de filme | |
| BR112017013471A2 (pt) | Pré-formulação, formulação farmacêutica, composição de depósito, métodos para administração de um agente bioativo a um organismo humano ou não humano, para preparação de uma composição cristalina líquida, para tratamento ou profilaxia de um indivíduo animal não humano ou humano, para administração de uma pré-formulação para um sujeito que dela necessita, processo para formação de uma pré- formulação, uso de uma mistura cristalina não líquida de baixa viscosidade, dispositivo de administração pré-preenchido, e, kit. | |
| CN109715138B (zh) | 前列环素类似物制剂 | |
| BR112012015016B8 (pt) | formulação farmacêutica, forma de dosagem farmacêutica entérica e uso de uma formulação | |
| BR112015018144A8 (pt) | composição de emulsão água/óleo farmacêutica estável com gotículas de óleo manométricas, método para fazer a mesma e alta dose única de clopidogrel usada para tratar um paciente | |
| Buysa et al. | Lipid emulsion therapy: non-nutritive uses of lipid emulsions in anaesthesia and intensive care | |
| JP5509090B2 (ja) | ピラゾロン誘導体のエマルジョン製剤 | |
| JP6374558B2 (ja) | 皮膚科障害または皮膚科疾患を処置するための新規製剤および方法 | |
| WO2012109151A1 (en) | Permeation enhancers with liposomes for topical formulations | |
| KR20150004798A (ko) | 소포성 제형 | |
| Suksaeree et al. | Formulation and in vitro study of ketoprofen pseudolatex gel for transdermal drug delivery systems | |
| BR112017012975B1 (pt) | Formulações injetáveis de paracetamol | |
| Cavalcanti et al. | Microemulsion for topical application of pentoxifylline: In vitrorelease andin vivoevaluation |